Trusted AI has huge potential to create long-term value for all stakeholders. But the cost of unethical application could be catastrophic. In this panel, experts from across different industries will discuss tangible use cases demonstrating the greater financial benefit to be derived from mitigating AI risk within the business and innovating responsibly.
Mitigating risk is a means to achieve optimal business outcomes and ethical concerns belong in the conversation. So how can organizations effectively bridge current divides between innovation and ethics, and catalyze previously impossible growth?
Betsy Greytok
VP of Ethics and Policy
IBM
Valeria Sadovykh
Technology Strategist
Microsoft
Oriana Medlicott
Senior Researcher - Technology & Innovation Strategy (Lead on AI Ethics)
Fujitsu
Oriana Medlicott is leading AI Ethics in the Technology Strategy Unit at Fujitsu. She is the co-founder and co-host of Let’s Chat Ethics Podcast and on the advisory board of the AI Ethics Journal at UCLA. Prior to Fujitsu, Oriana worked as an AI Ethics consultant with start-ups, think tanks and academia across the USA and Europe. In Autumn of 2022, Oriana will lecture introduction to AI Ethics in industry at Nottingham Trent University. She holds a Masters in Philosophy, looking at the Ethics of AI and Biotech.
Over the past few decades, several definitions of AI have surfaced. In its simplest form, AI combines computer science and robust datasets to enable problem-solving. But is AI technically just a model or should AI, machine learning and deep learning be categorized differently?
- Myth versus reality: what AI is and what it isn’t, what it can do and what it can’t
- The distinctions between artificial intelligence, machine learning, deep learning and neural networks
- Why those distinctions matter in terms of both determining the requisite risk considerations and identifying the most commercially viable use cases
AI has tremendous potential to create sustained long-term value – as long as you get it right. From day one of developing AI strategies, it is imperative that management understand the risks and the opportunities – and how ethics can influence them both
Aude Veinante
European Patent Attorney
Lavoix
Aude assists her clients in defining their patent strategy. Aude drafts new patent applications and monitors grant procedures in France and abroad. Her work also includes conducting patentability, validity and freedom to operate studies as well as forming consultations relative to supplementary protection certificates (SPCs).
Aude performs audits in the pharmaceutical and life science fields and advises her clients in case of patent disputes.
Aude is a member of the AIPPI (International Association for the Protection of Intellectual Property) and the GRAPI (Groupe Rhône-Alpes pour la protection de la Propriété Intellectuelle [Rhône-Alpes Group for the Protection of Intellectual Property]). She is also a lecturer at the Bordeaux National School of Biomolecule Technology.
Béatrice Holtz
Patent Attorney
Lavoix
Béatrice is a patent attorney at LAVOIX. She assists biotechnology companies, start-ups, universities, research entities, or multinationals, in technical fields including biotechnology, pharmaceutical products, cellular biology, immunology, enzymology, microbiology, plant biology and the food industry.
She has considerable experience preparing new patent applications as well as with patent prosecution, filing Supplementary Protection Certificates, and monitoring grant procedures in France and abroad.
Béatrice represents clients during opposition and appeal procedures before the European Patent Office. She also has extensive experience preparing opinions on freedom to operate, conducting audits on patent portfolios, infringement, invalidity & enforcement and due diligence examinations.
